Medical
-
Tiziana Life Sciences announced that a preclinical study of its intranasal foralumab in combination with semaglutide (Ozempic / Wegovy) demonstrated synergistic effects in a mouse model of obesity, improving liver function and reducing inflammation more… Read more . . .
-
MannKind Corporation has announced that data from a recently completed Phase 1 study of MNKD-201 nintedanib DPI support continued development of the inhaler for the treatment of idiopathic pulmonary fibrosis (IPF). MannKind had announced plans for… Read more . . .
-
Kither Biotech has announced the initiation of a Phase 1 trial of its KIT2014, an inhaled peptide that the company is developing as a CFTR enhancer for use as an add-on with CFTR modulators for… Read more . . .
-
Sensory Cloud has announced the publication of an article in ERJ Open Research presenting data from a study of its SC001 intranasal alkaline hypertonic divalent salt in patients with refractory chronic cough (RCC). The company… Read more . . .
-
AuraVax Therapeutics announced that the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a preclinical research contract to support evaluation of AuraVax’s NanoSTING-002 mucosal adjuvant… Read more . . .
-
Orexo announces the initiation of the OX640-002 trial of OX640 epinephrine nasal powder in people with allergic rhinitis, with results expected in early 2025. The new trial is expected to enroll 30 people with allergic… Read more . . .
-
AstraZeneca and Avillion have announced that the Phase 3b BATURA trial of Airsupra albuterol / budesonide MDI as a rescue inhaler in patients with mild asthma met its primary endpoint of reduction in risk of… Read more . . .
-
According to Qnovia (formerly Respira Technologies), the FDA has cleared an IND submitted by the company for a trial of its QN-01 RespiRx nicotine inhaler, which the company is developing for smoking cessation. The company says… Read more . . .
-
Transpire Bio has announced the initiation of its clinical program for a generic inhaler for the treatment of asthma and COPD. The company did not specify which of its pipeline products has been advanced into… Read more . . .
-
According to InCarda, data from the Phase 3 RESTORE-1 trial of FlecIH-103 flecainide inhalation solution for aroxysmal atrial fibrillation (PAF), which was initiated in July 2022, support continued development despite the early termination of the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden